Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial)

European Heart Journal

Volumn 19, Issue 1, 1998, Pages 85-95

  Janse, M J ^a   Malik, Marek ^b   Camm, A J ^b   Julian, D G ^c   Frangin, G A ^d   Schwartz, P J ^e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c Netherhall Gardens   (United Kingdom)

^d SANOFI   (France)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

Acute myocardial infarction; Amiodarone; Arrhythmias; Beta blockers; Heart rate; Left ventricular function

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PRIORITY JOURNAL; PROPHYLAXIS;

ADRENERGIC BETA-ANTAGONISTS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CLINICAL TRIALS; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; STROKE VOLUME;

EID: 0031888965     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1997.0823     Document Type: Article

References (29)

1. [1] Julian DG, Camm AJ, Frangin G et al. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-73.
2. [2] Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997; 349: 675-82.
3. [3] Singh SN, Fletcher SG, Fisher SG et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77-82.
4. [4] Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized trials. JAMA 1991; 266: 93-8.
5. [5] The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-7.
6. [6] Beta-Blocker Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-14.
7. [7] Kjekshus JK. Importance of heart rate in determining betablocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-49F.
8. [8] Copie X, Hnatkova K, Staunton A, Fei L, Camm AJ, Malik M. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two-year follow-up study. J Am Coll Cardiol 1996; 27: 270-6.
9. [9] Hartikainen JA, Malik M, Staunton A, Poloniecki J, Camm AJ. Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction. J Am Coll Cardiol 1996; 28: 296-304.
10. [10] The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309: 331-6.
11. [11] Ruberman W, Weinblatt E, Goldberg JD et al. Ventricular premature beats and mortality after myocardial infarction. N Engl J Med 1977; 297: 750-7.
12. [12] Lee KL, Woodlief LH, Topol EJ et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results of an international trial of 41,021 patients. Circulation 1995; 91: 1659-68.
13. [13] Josephson RA, Chahine RA, Morganroth J, Anderson J, Waldo A, Hallstrom A. Prediction of cardiac death in patients with a very low ejection fraction after myocardial infarction: a Cardiac Arrhythmia Suppression Trial (CAST) study. Am Heart J 1996; 130: 685-91.
14. [14] Disegni E, Goldbourt U, Reicher-Reiss H et al. The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. J Clin Epidemiol 1995; 48: 1197-205.
15. [15] Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989; 69: 1049-169
16. [16] Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992; 85 (Suppl I): 177-91.
17. [17] Feldman MD, Gwathmey JK, Phillips P, Schoen F, Morgan JP. Reversal of force-frequency relationship in working myocardium from patients with end-stage heart failure. J Appl Cardiol 1988; 3: 273-83.
18. [18] Singh BN. Amiodarone: pharmacological, electrophysiological, and clinical profile of an unusual antiarrhythmic compound. In: Singh BN, Wellens HJJ, Hiraoka M, eds. Electropharmacological control of cardiac arrhythmias. Mount Kisco, NY: Futura Publishing Company Inc., 1994: 497-522.
19. [19] Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997; 35: 13-29.
20. [20] Nul DR, Doval HC, Grancelli HO et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol 1997; 29: 1199-205.
21. [21] Moss AJ, Davis HT, De Camilla J, Bayer LW. Ventricular ectopic beats and their relation to sudden and nonsudden cardiac death after myocardial infarction. Circulation 1978; 60: 998-1003.
22. [22] Bigger Jr JT, Fleiss JL, Kleiger J et al. The relationship among ventricular arrhythmias, left ventricular dysfunction and mortality in two years after myocardial infarction. Circulation 1984; 69: 250-8.
23. [23] Budaj A, Kokowicz P, Smielak-Korombel W et al. Lack of effect of amiodarone after extensive infarction. Cor Art Dis 1996; 7: 315-19.
24. [24] Pfister M, Kiowski W, Burchhardt D, Follath F, Burhart F. Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol 1992; 69: 1399-402.
25. [25] Gill J, Heel RC, Fitton A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992; 43: 69-110.
26. [26] Marcus FI. Drug combinations and interactions with class III agents. J Cardiovasc Pharmacol 1992; 20 (Suppl 2): S70-S74.
27. [27] Counihan PJ, McKenna WJ. Risk benefit assessment of amiodarone in the treatment of cardiac arrhythmias. Drug Safety 1990; 5: 286-304.
28. [28] Green HL, Richardson DW, Barker AH et al. Classification of deaths after myocardial infarction as arrhythmic or non-arrhythmic (the Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989; 63: 1-6.
29. [29] Torp-Pedersen C, Køber L, Elming H, Burchart H. Classification of sudden and arrhythmic death. PACE 1997; 20: 2545-52.